论文部分内容阅读
尽管很多制造商把购并计划列入了2000年记事日程,但是,看起来寻求合适的合作伙伴不是件容易的事,2000年分析仪器领域实际的购并数量从1999年的75起下降到约40起。 两笔最大的收购是在生命科学领域,Invitro-gen公司花了19亿美元(1.90×10~9美元)收购了Life Technologies公司和其母公司—Dexter公司,并且将其分成两个部分,其中的一个将目标定在快速发展的基因市场。Invitrogen公司预言一年的收入约为5亿美元(500×10~6美元)。在这期间,PerkinElmer公司以4亿美元(400×10~6美元)的身价使自己成为NEN Life Sciences公司药品开发部门的三个主要供应商之一。同时,该公
Although many manufacturers included their mergers and acquisitions plan in the calendar of 2000, it seems that finding the right partner is not an easy task. The actual number of mergers and acquisitions in analytical instruments dropped from 75 in 1999 to about 40 in 2000 . Two of the biggest acquisitions were in the life sciences, where Invitro-gen spent $ 1.9 billion ($ 1.90 × 10- $ 9) in acquiring Life Technologies and its parent company, Dexter, and dividing it into two parts, One of the goals set in the rapidly growing genetic markets. Invitrogen predicted a year’s revenue of about 500 million US dollars (500 × 10 ~ 6 US dollars). In the meantime, PerkinElmer has made itself one of the three major suppliers of drug development at NEN Life Sciences for $ 400 million ($ 400 × 10 ~ $ 6). At the same time, the public